APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anemia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anemia Drugs Market Outlook and Growth Opportunities 2026

20 December 2025198 pages

Choose your research edition.

Industry ResearchAnemia Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Anemia Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Anemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anemia Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anemia Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Anemia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anemia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anemia Drugs market include Eli Lilly, GlaxoSmithKline, Bayer AG, Regen Biopharma, Pieris Pharmaceuticals, Onconova Therapeutics, Mast Therapeutics, GlycoMimetics and Global Blood Therapeutics (GBT), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anemia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anemia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anemia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anemia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anemia Drugs Segment by Company

Eli Lilly

GlaxoSmithKline

Bayer AG

Regen Biopharma

Pieris Pharmaceuticals

Onconova Therapeutics

Mast Therapeutics

GlycoMimetics

Global Blood Therapeutics (GBT)

Fibrogen

Celgene Corporation

Bluebird Bio

Akebia Therapeutics

Acceleron Pharma

Anemia Drugs Segment by Type

Oral

Injection

Anemia Drugs Segment by Application

Aplastic Anemia

Iron Deficiency Anemia

Chronic Kidney Disease related Anemia

Sickle Cell Anemia

Anemia Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anemia Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anemia Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anemia Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anemia Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anemia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anemia Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anemia Drugs industry.

Chapter 3: Detailed analysis of Anemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anemia Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anemia Drugs Industry Trends Table 2. Anemia Drugs Industry Drivers Table 3. Anemia Drugs Industry Opportunities and Challenges Table 4. Anemia Drugs Industry Restraints Table 5. Global Anemia Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anemia Drugs Revenue Share by Company (2021-2026) Table 7. Global Anemia Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anemia Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Anemia Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anemia Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anemia Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Anemia Drugs Company, Product Type & Application Table 13. Global Anemia Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anemia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Global Anemia Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anemia Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anemia Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anemia Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Anemia Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Anemia Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anemia Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anemia Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anemia Drugs Sales Value Share by Type (2021-2026) Table 28. Global Anemia Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Aplastic Anemia Table 30. Significant Companies of Iron Deficiency Anemia Table 31. Significant Companies of Chronic Kidney Disease related Anemia Table 32. Significant Companies of Sickle Cell Anemia Table 33. Global Anemia Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Anemia Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Anemia Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Anemia Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Anemia Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Anemia Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anemia Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Anemia Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Anemia Drugs Sales Value Share by Application (2021-2026) Table 42. Global Anemia Drugs Sales Value Share by Application (2027-2032) Table 43. Global Anemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Anemia Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Anemia Drugs Sales Market Share by Region (2021-2026) Table 46. Global Anemia Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Anemia Drugs Sales Market Share by Region (2027-2032) Table 48. Global Anemia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Anemia Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Anemia Drugs Sales Value Share by Region (2021-2026) Table 51. Global Anemia Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Anemia Drugs Sales Value Share by Region (2027-2032) Table 53. Global Anemia Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Anemia Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Anemia Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Anemia Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Anemia Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Anemia Drugs Sales Market Share by Country (2021-2026) Table 59. Global Anemia Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Anemia Drugs Sales Market Share by Country (2027-2032) Table 61. Global Anemia Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Anemia Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Anemia Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Anemia Drugs Sales Value Market Share by Country (2027-2032) Table 65. Eli Lilly Company Information Table 66. Eli Lilly Business Overview Table 67. Eli Lilly Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Eli Lilly Anemia Drugs Product Portfolio Table 69. Eli Lilly Recent Development Table 70. GlaxoSmithKline Company Information Table 71. GlaxoSmithKline Business Overview Table 72. GlaxoSmithKline Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline Anemia Drugs Product Portfolio Table 74. GlaxoSmithKline Recent Development Table 75. Bayer AG Company Information Table 76. Bayer AG Business Overview Table 77. Bayer AG Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Bayer AG Anemia Drugs Product Portfolio Table 79. Bayer AG Recent Development Table 80. Regen Biopharma Company Information Table 81. Regen Biopharma Business Overview Table 82. Regen Biopharma Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Regen Biopharma Anemia Drugs Product Portfolio Table 84. Regen Biopharma Recent Development Table 85. Pieris Pharmaceuticals Company Information Table 86. Pieris Pharmaceuticals Business Overview Table 87. Pieris Pharmaceuticals Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pieris Pharmaceuticals Anemia Drugs Product Portfolio Table 89. Pieris Pharmaceuticals Recent Development Table 90. Onconova Therapeutics Company Information Table 91. Onconova Therapeutics Business Overview Table 92. Onconova Therapeutics Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Onconova Therapeutics Anemia Drugs Product Portfolio Table 94. Onconova Therapeutics Recent Development Table 95. Mast Therapeutics Company Information Table 96. Mast Therapeutics Business Overview Table 97. Mast Therapeutics Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Mast Therapeutics Anemia Drugs Product Portfolio Table 99. Mast Therapeutics Recent Development Table 100. GlycoMimetics Company Information Table 101. GlycoMimetics Business Overview Table 102. GlycoMimetics Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GlycoMimetics Anemia Drugs Product Portfolio Table 104. GlycoMimetics Recent Development Table 105. Global Blood Therapeutics (GBT) Company Information Table 106. Global Blood Therapeutics (GBT) Business Overview Table 107. Global Blood Therapeutics (GBT) Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio Table 109. Global Blood Therapeutics (GBT) Recent Development Table 110. Fibrogen Company Information Table 111. Fibrogen Business Overview Table 112. Fibrogen Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Fibrogen Anemia Drugs Product Portfolio Table 114. Fibrogen Recent Development Table 115. Celgene Corporation Company Information Table 116. Celgene Corporation Business Overview Table 117. Celgene Corporation Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Celgene Corporation Anemia Drugs Product Portfolio Table 119. Celgene Corporation Recent Development Table 120. Bluebird Bio Company Information Table 121. Bluebird Bio Business Overview Table 122. Bluebird Bio Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Bluebird Bio Anemia Drugs Product Portfolio Table 124. Bluebird Bio Recent Development Table 125. Akebia Therapeutics Company Information Table 126. Akebia Therapeutics Business Overview Table 127. Akebia Therapeutics Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Akebia Therapeutics Anemia Drugs Product Portfolio Table 129. Akebia Therapeutics Recent Development Table 130. Acceleron Pharma Company Information Table 131. Acceleron Pharma Business Overview Table 132. Acceleron Pharma Anemia Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Acceleron Pharma Anemia Drugs Product Portfolio Table 134. Acceleron Pharma Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Anemia Drugs Distributors List Table 138. Anemia Drugs Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Anemia Drugs Product Image Figure 2. Global Anemia Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anemia Drugs Sales (2021-2032) & (K Units) Figure 5. Global Anemia Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anemia Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Global Anemia Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anemia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anemia Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Anemia Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anemia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anemia Drugs Sales Value Share by Type (2021-2032) Figure 17. Aplastic Anemia Image Figure 18. Iron Deficiency Anemia Image Figure 19. Chronic Kidney Disease related Anemia Image Figure 20. Sickle Cell Anemia Image Figure 21. Global Anemia Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Anemia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Anemia Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Anemia Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Anemia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Anemia Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Anemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Anemia Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Anemia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Anemia Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Anemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Anemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Anemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Anemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Anemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Anemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Anemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Anemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Anemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Anemia Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Anemia Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Aplastic Anemia
  • Iron Deficiency Anemia
  • Chronic Kidney Disease related Anemia
  • Sickle Cell Anemia
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Bayer AG
  • Regen Biopharma
  • Pieris Pharmaceuticals
  • Onconova Therapeutics
  • Mast Therapeutics
  • GlycoMimetics
  • Global Blood Therapeutics (GBT)
  • Fibrogen
  • Celgene Corporation
  • Bluebird Bio
  • Akebia Therapeutics
  • Acceleron Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anemia Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Anemia Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Anemia Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anemia Drugs Market Dynamics
  1. 2.1 Anemia Drugs Industry Trends
  2. 2.2 Anemia Drugs Industry Drivers
  3. 2.3 Anemia Drugs Industry Opportunities and Challenges
  4. 2.4 Anemia Drugs Industry Restraints
3 Anemia Drugs Market by Company
  1. 3.1 Global Anemia Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anemia Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anemia Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Anemia Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Anemia Drugs Company Ranking (2024-2026)
  6. 3.6 Global Anemia Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Anemia Drugs Company Product Type and Application
  8. 3.8 Global Anemia Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anemia Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anemia Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anemia Drugs Market by Type
  1. 4.1 Anemia Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Anemia Drugs Sales Volume by Type
  5. 4.2.1 Global Anemia Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anemia Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anemia Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anemia Drugs Sales Value by Type
  9. 4.3.1 Global Anemia Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anemia Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anemia Drugs Sales Value Share by Type (2021-2032)
5 Anemia Drugs Market by Application
  1. 5.1 Anemia Drugs Application Introduction
  2. 5.1.1 Aplastic Anemia
  3. 5.1.2 Iron Deficiency Anemia
  4. 5.1.3 Chronic Kidney Disease related Anemia
  5. 5.1.4 Sickle Cell Anemia
  6. 5.2 Global Anemia Drugs Sales Volume by Application
  7. 5.2.1 Global Anemia Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anemia Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Anemia Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Anemia Drugs Sales Value by Application
  11. 5.3.1 Global Anemia Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anemia Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Anemia Drugs Sales Value Share by Application (2021-2032)
6 Anemia Drugs Regional Sales and Value Analysis
  1. 6.1 Global Anemia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anemia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anemia Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Anemia Drugs Sales by Region (2027-2032)
  5. 6.3 Global Anemia Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anemia Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anemia Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anemia Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Anemia Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anemia Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Anemia Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anemia Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Anemia Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anemia Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anemia Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anemia Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Anemia Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anemia Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anemia Drugs Sales Value Share by Country, 2025 VS 2032
7 Anemia Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Anemia Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anemia Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anemia Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Anemia Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Anemia Drugs Sales by Country (2027-2032)
  6. 7.4 Global Anemia Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anemia Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anemia Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anemia Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anemia Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anemia Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anemia Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anemia Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anemia Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anemia Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anemia Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anemia Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anemia Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anemia Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anemia Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anemia Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anemia Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anemia Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anemia Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anemia Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anemia Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anemia Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anemia Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anemia Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anemia Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anemia Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anemia Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anemia Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anemia Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anemia Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anemia Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anemia Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anemia Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anemia Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Anemia Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Anemia Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Bayer AG
  14. 8.3.1 Bayer AG Company Information
  15. 8.3.2 Bayer AG Business Overview
  16. 8.3.3 Bayer AG Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG Anemia Drugs Product Portfolio
  18. 8.3.5 Bayer AG Recent Developments
  19. 8.4 Regen Biopharma
  20. 8.4.1 Regen Biopharma Company Information
  21. 8.4.2 Regen Biopharma Business Overview
  22. 8.4.3 Regen Biopharma Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regen Biopharma Anemia Drugs Product Portfolio
  24. 8.4.5 Regen Biopharma Recent Developments
  25. 8.5 Pieris Pharmaceuticals
  26. 8.5.1 Pieris Pharmaceuticals Company Information
  27. 8.5.2 Pieris Pharmaceuticals Business Overview
  28. 8.5.3 Pieris Pharmaceuticals Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pieris Pharmaceuticals Anemia Drugs Product Portfolio
  30. 8.5.5 Pieris Pharmaceuticals Recent Developments
  31. 8.6 Onconova Therapeutics
  32. 8.6.1 Onconova Therapeutics Company Information
  33. 8.6.2 Onconova Therapeutics Business Overview
  34. 8.6.3 Onconova Therapeutics Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Onconova Therapeutics Anemia Drugs Product Portfolio
  36. 8.6.5 Onconova Therapeutics Recent Developments
  37. 8.7 Mast Therapeutics
  38. 8.7.1 Mast Therapeutics Company Information
  39. 8.7.2 Mast Therapeutics Business Overview
  40. 8.7.3 Mast Therapeutics Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mast Therapeutics Anemia Drugs Product Portfolio
  42. 8.7.5 Mast Therapeutics Recent Developments
  43. 8.8 GlycoMimetics
  44. 8.8.1 GlycoMimetics Company Information
  45. 8.8.2 GlycoMimetics Business Overview
  46. 8.8.3 GlycoMimetics Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlycoMimetics Anemia Drugs Product Portfolio
  48. 8.8.5 GlycoMimetics Recent Developments
  49. 8.9 Global Blood Therapeutics (GBT)
  50. 8.9.1 Global Blood Therapeutics (GBT) Company Information
  51. 8.9.2 Global Blood Therapeutics (GBT) Business Overview
  52. 8.9.3 Global Blood Therapeutics (GBT) Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio
  54. 8.9.5 Global Blood Therapeutics (GBT) Recent Developments
  55. 8.10 Fibrogen
  56. 8.10.1 Fibrogen Company Information
  57. 8.10.2 Fibrogen Business Overview
  58. 8.10.3 Fibrogen Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Fibrogen Anemia Drugs Product Portfolio
  60. 8.10.5 Fibrogen Recent Developments
  61. 8.11 Celgene Corporation
  62. 8.11.1 Celgene Corporation Company Information
  63. 8.11.2 Celgene Corporation Business Overview
  64. 8.11.3 Celgene Corporation Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Celgene Corporation Anemia Drugs Product Portfolio
  66. 8.11.5 Celgene Corporation Recent Developments
  67. 8.12 Bluebird Bio
  68. 8.12.1 Bluebird Bio Company Information
  69. 8.12.2 Bluebird Bio Business Overview
  70. 8.12.3 Bluebird Bio Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bluebird Bio Anemia Drugs Product Portfolio
  72. 8.12.5 Bluebird Bio Recent Developments
  73. 8.13 Akebia Therapeutics
  74. 8.13.1 Akebia Therapeutics Company Information
  75. 8.13.2 Akebia Therapeutics Business Overview
  76. 8.13.3 Akebia Therapeutics Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Akebia Therapeutics Anemia Drugs Product Portfolio
  78. 8.13.5 Akebia Therapeutics Recent Developments
  79. 8.14 Acceleron Pharma
  80. 8.14.1 Acceleron Pharma Company Information
  81. 8.14.2 Acceleron Pharma Business Overview
  82. 8.14.3 Acceleron Pharma Anemia Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Acceleron Pharma Anemia Drugs Product Portfolio
  84. 8.14.5 Acceleron Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anemia Drugs Value Chain Analysis
  2. 9.1.1 Anemia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anemia Drugs Sales Mode & Process
  6. 9.2 Anemia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anemia Drugs Distributors
  9. 9.2.3 Anemia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst